BioLineRx (BLRX) Gross Margin (2024 - 2025)
BioLineRx (BLRX) posted Gross Margin of 79.38% for Q4 2025, down 1.18% on a QoQ basis from 80.33% in Q3 2025, and up 3121.0% year-over-year from 2.46% in Q4 2024.
BioLineRx (BLRX) has 2 years of Gross Margin data on file, last reported at 79.38% in Q4 2025.
- In Q4 2025, Gross Margin rose 3121.0% year-over-year to 79.38%; the TTM figure through Dec 2025 stood at 80.51% (up 1252.0% YoY), while the FY2025 annual figure was 80.51%, up 1252.0% from the prior year.
- Gross Margin fell to 79.38% in Q4 2025, from 80.33% in the prior quarter.
- Across five years, Gross Margin topped out at 86.67% in Q1 2025 and bottomed at 48.17% in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 79.04% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 86.85% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 91.79% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 82.22% |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | 79.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 79.38% |
| Sep 30, 2025 | 80.33% |
| Jun 30, 2025 | 76.32% |
| Mar 31, 2025 | 86.67% |
| Dec 31, 2024 | 48.17% |
| Sep 30, 2024 | 83.37% |
| Jun 30, 2024 | 83.37% |
| Mar 31, 2024 | 78.77% |